Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...
The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...
Regeneron recently announced it would initiate a quarterly dividend of $0.88, a competitive amount for a company first ...
The Federal Circuit upheld a preliminary injunction blocking the launch of a Celltrion Inc. biosimilar version to Regeneron ...
At the heart of the controversy is Regeneron's alleged practice of paying credit card fees to distributors, on the condition that these fees were not passed on to Eylea customers. This arrangement, ...
2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...
The US Court of Appeals for the Federal Circuit on Friday ruled against Regeneron in a closely-watched patent infringement ...
New York biotech scores win as Fed Circ upholds preliminary injunction against Celltrion's biosimilar launch | Ruling follows ...
Adjusted SG&A expenses increased 9% to $681 million due to higher commercialization-related expenses to support the launch of Eylea HD and higher headcount-related costs. Regeneron recorded ...
2. Transition to Eylea HD: In response to competitive pressures, Regeneron is actively working to transition patients to Eylea HD, a higher-dose formulation. This strategy aims to maintain market ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results